Ecor1 Capital, LLC

EcoR1 Capital is a San Francisco-based fundamental biotechnology-focused investment advisory firm, active in private equity and hedge fund asset classes, established in 2012. The firm evaluates and selects exceptional biotechnology companies, aiming to advance medical research through investments in compelling biotech companies developing promising new solutions for untreated diseases.

 Oleg Nodelman

Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment firm established in 2013. With over 20 years of experience in biotech investing, he previously served as a portfolio manager at BVF Partners. Mr. Nodelman currently sits on the boards of AnaptysBio (ANAB), Galapagos (GLPG), and Zymeworks (ZYME). He holds a B.S. in Foreign Service with a concentration in Science and Technology from Georgetown University.

 Areesha Saif

Areesha Saif is an Analyst at EcoR1 and is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. Prior to joining EcoR1 in 2024, Ms. Saif spent two years at Deloitte, where she advised pharmaceutical and biotech companies on their market launch and growth strategies. Areesha holds a Master of Science and a Bachelor of Arts in Natural Sciences, with a specialization in Chemistry, from the University of Cambridge.

 Nima Emami

Nima Emami is an Analyst with EcoR1 and is responsible for due diligence and analysis of value-oriented investment opportunities. Prior to joining EcoR1 in 2024, Mr. Emami led a venture-backed biotechnology company. Mr. Emami holds a Ph.D. from the University of California, San Francisco (UCSF), and a Bachelor of Science degree in Bioengineering, Electrical Engineering and Computer Science from the University of California, Berkeley.

Nil

Companies with fund stakes involved in activist actions such as 13D filing(s) or proxy campaign(s).